Potential use of DPYSL2 as a “glioma versus reference” tissue biomarker, and the roles of some of the suggested biomarkers for class differentiation have been confirmed with qPCR on a small scale study, but need to be validated with a larger sample number. Here, DPYSL2 is linked to central nervous system cancer.